When a surgeon needs to repair a gap in shattered bone — left by trauma, infection, or tumour surgery — the standard materials are calcium-based ceramics or synthetic fillers. In Pune, Serigen Mediproducts has spent more than a decade proving the best material for the job might be one India has woven for millennia: silk.
The science began as fundamental biomaterials research led by Dr Anuya Nisal at the CSIR-National Chemical Laboratory (CSIR-NCL) in Pune. To turn those insights into products a surgeon could trust, Serigen Mediproducts was founded in 2015 — then called BiolMed Innovations — alongside Dr Premnath Venugopalan and Dr Swati Shukla. At the heart of the company is a patented process: solution reprocessing of silk, which transforms ordinary silk threads into a structured, high-strength porous material that the body accepts. The path from bench to operating table was nurtured by India’s deep-tech ecosystem — the company was incubated at Venture Center and received early backing from the Biotechnology Industry Research Assistance Council (BIRAC).
On October 12, 2026, Serigen officially launched its flagship product commercially: Serioss, an osteoconductive bone void filler powered by silk protein, designed to fill bone cavities caused by trauma, infection or cancer while giving bone cells the right environment to thrive and rebuild. The company describes Serioss as the world’s first silk-protein bone void filler to complete comprehensive clinical trials and secure full regulatory approvals. The launch also marked the inauguration of Serigen’s ISO 13485-certified manufacturing facility in Pune, and the company has secured the CDSCO licence for manufacturing and sale.
The clinical foundation behind Serioss is built on years of human data. A pilot clinical trial at Sancheti Hospital in Pune completed a rigorous three-year follow-up, demonstrating sustained safety and successful bone remodelling, the company says. Serigen then completed a pivotal, multicentre clinical trial across premier medical centres in India; in comparative evaluations, Serioss showed superior new bone formation and structural recovery relative to leading global synthetic bone void fillers, according to the company — a strong showing for silk protein as a platform for complex bone reconstruction.
Serioss is the second act of a growing silk portfolio. Serigen’s first commercialised product, Seriderm, is an advanced silk-protein wound dressing used for acute and complex chronic wounds — diabetic foot ulcers, bed sores and burns. Serimat, a silk-protein composite matrix for soft-tissue reconstruction including post-oncological breast surgery, is in the pipeline. The company holds patents across India, the US, Europe and Japan, and has collected national honours including the first Dr K.H. Gharda Industrial Innovation Award in Polymer Science and the 9th National Award for Polymers in Public Healthcare from the Department of Chemicals and Petrochemicals. It also won the Poster Pitch competition at the Orthopaedic Research Society’s 2024 annual meeting in the US.
There is a deeper Indian story here too. India is the world’s second-largest producer of silkworm silk — an abundant indigenous bioresource that Serigen converts into high-value medical devices at its Pune facility, rather than importing synthetic grafts at a premium. Backed by a Rs 10-crore round led by IAN Alpha Fund and Colossa Ventures, the company is now taking Serioss from launch to operating rooms across the country. Silk wove India’s past; in Serigen’s hands, it is stitching together its future.
